Literature DB >> 20124486

Irreversible electroporation therapy in the liver: longitudinal efficacy studies in a rat model of hepatocellular carcinoma.

Yang Guo1, Yue Zhang, Rachel Klein, Grace M Nijm, Alan V Sahakian, Reed A Omary, Guang-Yu Yang, Andrew C Larson.   

Abstract

Irreversible electroporation (IRE) is an innovative local-regional therapy that involves delivery of intense electrical pulses to tissue to induce nanoscale cell membrane defects for tissue ablation. The purpose of this study was to investigate the feasibility of using IRE as a liver-directed ablation technique for the treatment of hepatocellular carcinoma (HCC). In the N1-S1 rodent model, hepatomas were grown in 30 Sprague-Dawley rats that were divided into treatment and control groups. For treatment groups, IRE electrodes were inserted and eight 100-mus 2,500-V pulses were applied to ablate the targeted tumor tissues. For both groups, magnetic resonance imaging scans were performed at baseline and 15-day follow-up intervals to determine tumor sizes (one-dimensional maximum diameter, D(max); estimated two-dimensional cross-sectional area, C(max)) as a tactic to assess longitudinal outcomes. Additional groups of treated animals were sacrificed at 1-, 3-, and 7-day intervals posttherapy for pathology assessment of treatment response. Magnetic resonance images showed significant tumor size reductions within 15 days posttherapy (32 +/- 31% D(max) and 52 +/- 39% C(max) decreases compared with 110 +/- 35% D(max) and 286 +/- 125% C(max) increases for untreated tumors). Pathology correlation studies documented progression from poorly differentiated viable HCC tissues before treatment to extensive tumor necrosis and full regression in 9 of 10 treated rats 7 to 15 days after treatment. Our findings suggest that IRE can be an effective strategy for targeted ablation of liver tumors, prompting its further evaluation for HCC therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20124486      PMCID: PMC2822885          DOI: 10.1158/0008-5472.CAN-09-3067

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  42 in total

1.  A validated model of in vivo electric field distribution in tissues for electrochemotherapy and for DNA electrotransfer for gene therapy.

Authors:  D Miklavcic; D Semrov; H Mekid; L M Mir
Journal:  Biochim Biophys Acta       Date:  2000-09-01

Review 2.  Minimally invasive treatment of malignant hepatic tumors: at the threshold of a major breakthrough.

Authors:  G D Dodd; M C Soulen; R A Kane; T Livraghi; W R Lees; Y Yamashita; A R Gillams; O I Karahan; H Rhim
Journal:  Radiographics       Date:  2000 Jan-Feb       Impact factor: 5.333

3.  Caspase inhibition reduces apoptotic death of cryopreserved porcine hepatocytes.

Authors:  T Yagi; J A Hardin; Y M Valenzuela; H Miyoshi; G J Gores; S L Nyberg
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

4.  Malignant liver tumors treated with MR imaging-guided laser-induced thermotherapy: technique and prospective results.

Authors:  T J Vogl; P K Müller; R Hammerstingl; N Weinhold; M G Mack; C Philipp; M Deimling; J Beuthan; W Pegios; H Riess
Journal:  Radiology       Date:  1995-07       Impact factor: 11.105

Review 5.  Hepatocellular carcinoma.

Authors:  Josep M Llovet; Andrew Burroughs; Jordi Bruix
Journal:  Lancet       Date:  2003-12-06       Impact factor: 79.321

6.  Radio-frequency tissue ablation: effect of pharmacologic modulation of blood flow on coagulation diameter.

Authors:  S N Goldberg; P F Hahn; E F Halpern; R M Fogle; G S Gazelle
Journal:  Radiology       Date:  1998-12       Impact factor: 11.105

7.  Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma.

Authors:  R Vilana; J Bruix; C Bru; C Ayuso; M Solé; J Rodés
Journal:  Hepatology       Date:  1992-08       Impact factor: 17.425

8.  Improved coagulation with saline solution pretreatment during radiofrequency tumor ablation in a canine model.

Authors:  Muneeb Ahmed; S Melvyn Lobo; Joseph Weinstein; Jonathan B Kruskal; G Scott Gazelle; Elkan F Halpern; S Karim Afzal; Robert E Lenkinski; S Nahum Goldberg
Journal:  J Vasc Interv Radiol       Date:  2002-07       Impact factor: 3.464

9.  Locoregional recurrences are frequent after radiofrequency ablation for hepatocellular carcinoma.

Authors:  Lawrence E Harrison; Baburao Koneru; Phil Baramipour; Adrian Fisher; Alison Barone; Dorian Wilson; Andrew Dela Torre; Kyunghee C Cho; Daniel Contractor; Maria Korogodsky
Journal:  J Am Coll Surg       Date:  2003-11       Impact factor: 6.113

10.  Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection.

Authors:  T Livraghi; A Giorgio; G Marin; A Salmi; I de Sio; L Bolondi; M Pompili; F Brunello; S Lazzaroni; G Torzilli
Journal:  Radiology       Date:  1995-10       Impact factor: 11.105

View more
  53 in total

1.  Electroporation-mediated transcatheter arterial chemoembolization in the rabbit VX2 liver tumor model.

Authors:  Yang Guo; Yue Zhang; Ning Jin; Rachel Klein; Jodi Nicolai; Robert J Lewandowski; Robert K Ryu; Reed A Omary; Andrew C Larson
Journal:  Invest Radiol       Date:  2012-02       Impact factor: 6.016

2.  Rapid dramatic alterations to the tumor microstructure in pancreatic cancer following irreversible electroporation ablation.

Authors:  Zhuoli Zhang; Weiguo Li; Daniel Procissi; Patrick Tyler; Reed A Omary; Andrew C Larson
Journal:  Nanomedicine (Lond)       Date:  2013-09-11       Impact factor: 5.307

3.  Image-guided local delivery strategies enhance therapeutic nanoparticle uptake in solid tumors.

Authors:  Samdeep K Mouli; Patrick Tyler; Joseph L McDevitt; Aaron C Eifler; Yang Guo; Jodi Nicolai; Robert J Lewandowski; Weiguo Li; Daniel Procissi; Robert K Ryu; Y Andrew Wang; Riad Salem; Andrew C Larson; Reed A Omary
Journal:  ACS Nano       Date:  2013-08-20       Impact factor: 15.881

4.  MR imaging enables measurement of therapeutic nanoparticle uptake in rat N1-S1 liver tumors after nanoablation.

Authors:  Joseph L McDevitt; Samdeep K Mouli; Patrick D Tyler; Weiguo Li; Jodi Nicolai; Daniele Procissi; Ann B Ragin; Y Andrew Wang; Robert J Lewandowski; Riad Salem; Andrew C Larson; Reed A Omary
Journal:  J Vasc Interv Radiol       Date:  2014-05-20       Impact factor: 3.464

5.  Diffusion MRI biomarkers predict the outcome of irreversible electroporation in a pancreatic tumor mouse model.

Authors:  Matteo Figini; Xifu Wang; Tianchu Lyu; Zhanliang Su; Bin Wang; Chong Sun; Junjie Shangguan; Liang Pan; Kang Zhou; Quanhong Ma; Vahid Yaghmai; Daniele Procissi; Andrew C Larson; Zhuoli Zhang
Journal:  Am J Cancer Res       Date:  2018-08-01       Impact factor: 6.166

6.  Enhancing Irreversible Electroporation by Manipulating Cellular Biophysics with a Molecular Adjuvant.

Authors:  Jill W Ivey; Eduardo L Latouche; Megan L Richards; Glenn J Lesser; Waldemar Debinski; Rafael V Davalos; Scott S Verbridge
Journal:  Biophys J       Date:  2017-07-25       Impact factor: 4.033

7.  Preclinical and clinical evaluation of the liver tumor irreversible electroporation by magnetic resonance imaging.

Authors:  Matteo Figini; Xifu Wang; Tianchu Lyu; Zhanliang Su; Daniele Procissi; Vahid Yaghmai; Andrew C Larson; Zhuoli Zhang
Journal:  Am J Transl Res       Date:  2017-02-15       Impact factor: 4.060

Review 8.  Advances in managing hepatocellular carcinoma.

Authors:  Marielle Reataza; David K Imagawa
Journal:  Front Med       Date:  2014-05-08       Impact factor: 4.592

9.  Multimodality imaging to assess immediate response to irreversible electroporation in a rat liver tumor model.

Authors:  Yue Zhang; Sarah B White; Jodi R Nicolai; Zhuoli Zhang; Derek L West; Dong-Hyun Kim; A Lee Goodwin; Frank H Miller; Reed A Omary; Andrew C Larson
Journal:  Radiology       Date:  2014-02-18       Impact factor: 11.105

10.  Ablation of colorectal liver metastases by irreversible electroporation: results of the COLDFIRE-I ablate-and-resect study.

Authors:  H J Scheffer; K Nielsen; A A J M van Tilborg; J M Vieveen; R A Bouwman; G Kazemier; H W M Niessen; S Meijer; C van Kuijk; M P van den Tol; M R Meijerink
Journal:  Eur Radiol       Date:  2014-06-18       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.